Ligand id: 8376

Name: ertugliflozin

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 6
Hydrogen bond donors 4
Rotatable bonds 6
Topological polar surface area 108.61
Molecular weight 436.13
XLogP 3.05
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Ertugliflozin is being evaluated in Phase III clinical trials as a potential treatment for type 2 diabetes mellitus (T2DM).
Mechanism Of Action and Pharmacodynamic Effects
Ertugliflozin inhibits sodium glucose co-transporter-2 (gene symbol SLC5A2), a protein responsible for renal reabsorption of blood glucose. Inhibition of the transporter promotes urinary excretion of glucose [1,3].